Skip to main content
NCBI home page
The Texas Heart Institute Journal logoLink to The Texas Heart Institute Journal
. 1990;17(1):5–9.

A Clinical View of Vancomycin in 1990

W Terry Siebert 1
PMCID: PMC324894  PMID: 15227183

Full text

PDF
5

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker C. N., Thornsberry C., Facklam R. R. Synergism, killing kinetics, and antimicrobial susceptibility of group A and B streptococci. Antimicrob Agents Chemother. 1981 May;19(5):716–725. doi: 10.1128/aac.19.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bayer A. S., Morrison J. O. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1984 Aug;26(2):220–223. doi: 10.1128/aac.26.2.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brummett R. E., Fox K. E. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother. 1989 Jun;33(6):791–796. doi: 10.1128/aac.33.6.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bunke C. M., Aronoff G. R., Brier M. E., Sloan R. S., Luft F. C. Vancomycin kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1983 Nov;34(5):631–637. doi: 10.1038/clpt.1983.225. [DOI] [PubMed] [Google Scholar]
  5. Cherubin C. E., Corrado M. L., Sierra M. F., Gombert M. E., Shulman M. Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and N-formimidoyl thienamycin. Antimicrob Agents Chemother. 1981 Oct;20(4):553–555. doi: 10.1128/aac.20.4.553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eng R. H., Smith S. M., Goldstein E. J., Miyasaki K. T., Quah S. E., Buccini F. Failure of vancomycin prophylaxis and treatment for Actinobacillus actinomycetemcomitans endocarditis. Antimicrob Agents Chemother. 1986 Apr;29(4):699–700. doi: 10.1128/aac.29.4.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Farber B. F., Moellering R. C., Jr Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother. 1983 Jan;23(1):138–141. doi: 10.1128/aac.23.1.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. George W. L., Rolfe R. D., Harding G. K., Klein R., Putnam C. W., Finegold S. M. Clostridium difficile and cytotoxin in feces of patients with antimicrobial agent-associated pseudomembranous colitis. Infection. 1982;10(4):205–208. doi: 10.1007/BF01666910. [DOI] [PubMed] [Google Scholar]
  9. Gombert M. E., Landesman S. H., Corrado M. L., Stein S. C., Melvin E. T., Cummings M. Vancomycin and rifampin therapy for Staphylococcus epidermidis meningitis associated with CSF shunts: report of three cases. J Neurosurg. 1981 Oct;55(4):633–636. doi: 10.3171/jns.1981.55.4.0633. [DOI] [PubMed] [Google Scholar]
  10. Gopal V., Bisno A. L., Silverblatt F. J. Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations. JAMA. 1976 Oct 4;236(14):1604–1606. [PubMed] [Google Scholar]
  11. Gump D. W. Vancomycin for treatment of bacterial meningitis. Rev Infect Dis. 1981 Nov-Dec;3 Suppl:S289–S292. [PubMed] [Google Scholar]
  12. Jadeja L., Fainstein V., LeBlanc B., Bodey G. P. Comparative in vitro activities of teichomycin and other antibiotics against JK diphtheroids. Antimicrob Agents Chemother. 1983 Aug;24(2):145–146. doi: 10.1128/aac.24.2.145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Karchmer A. W., Archer G. L., Dismukes W. E. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med. 1983 Apr;98(4):447–455. doi: 10.7326/0003-4819-98-4-447. [DOI] [PubMed] [Google Scholar]
  14. Leclercq R., Derlot E., Weber M., Duval J., Courvalin P. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium. Antimicrob Agents Chemother. 1989 Jan;33(1):10–15. doi: 10.1128/aac.33.1.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Little W. A., Thomson L. A., Bowen W. H. Antibiotic susceptibility of Streptococcus mutans: comparison of serotype profiles. Antimicrob Agents Chemother. 1979 Mar;15(3):440–443. doi: 10.1128/aac.15.3.440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Liñares J., Perez J. L., Garau J., Murgui L., Martín R. Comparative susceptibilities of penicillin-resistant pneumococci to co-trimoxazole, vancomycin, rifampicin and fourteen beta-lactam antibiotics. J Antimicrob Chemother. 1984 Apr;13(4):353–359. doi: 10.1093/jac/13.4.353. [DOI] [PubMed] [Google Scholar]
  17. Moellering R. C., Jr, Krogstad D. J., Greenblatt D. J. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med. 1981 Mar;94(3):343–346. doi: 10.7326/0003-4819-94-3-343. [DOI] [PubMed] [Google Scholar]
  18. Neu H. C., Labthavikul P. In vitro activity of teichomycin compared with those of other antibiotics. Antimicrob Agents Chemother. 1983 Sep;24(3):425–428. doi: 10.1128/aac.24.3.425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Polk R. E., Healy D. P., Schwartz L. B., Rock D. T., Garson M. L., Roller K. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis. 1988 Mar;157(3):502–507. doi: 10.1093/infdis/157.3.502. [DOI] [PubMed] [Google Scholar]
  20. Reesor C., Chow A. W., Kureishi A., Jewesson P. J. Kinetics of intraventricular vancomycin in infections of cerebrospinal fluid shunts. J Infect Dis. 1988 Nov;158(5):1142–1143. doi: 10.1093/infdis/158.5.1142. [DOI] [PubMed] [Google Scholar]
  21. Riley P. S., Hollis D. G., Utter G. B., Weaver R. E., Baker C. N. Characterization and identification of 95 diphtheroid (group JK) cultures isolated from clinical specimens. J Clin Microbiol. 1979 Mar;9(3):418–424. doi: 10.1128/jcm.9.3.418-424.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rubin L. G., Vellozzi E., Shapiro J., Isenberg H. D. Infection with vancomycin-resistant "streptococci" due to Leuconostoc species. J Infect Dis. 1988 Jan;157(1):216–216. doi: 10.1093/infdis/157.1.216. [DOI] [PubMed] [Google Scholar]
  23. Schwalbe R. S., Stapleton J. T., Gilligan P. H. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med. 1987 Apr 9;316(15):927–931. doi: 10.1056/NEJM198704093161507. [DOI] [PubMed] [Google Scholar]
  24. Shulman S. T., Amren D. P., Bisno A. L., Dajani A. S., Durack D. T., Gerber M. A., Kaplan E. L., Millard H. D., Sanders W. E., Schwartz R. H. Prevention of Bacterial Endocarditis. A statement for health professionals by the Committee on Rheumatic Fever and Infective Endocarditis of the Council on Cardiovascular Disease in the Young. Circulation. 1984 Dec;70(6):1123A–1127A. [PubMed] [Google Scholar]
  25. Shuttleworth R., Taylor M., Jones D. M. Antimicrobial susceptibilities of Clostridium difficile. J Clin Pathol. 1980 Oct;33(10):1002–1005. doi: 10.1136/jcp.33.10.1002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Siebert W. T., Moreland N., Williams T. W., Jr Synergy of vancomycin plus cefazolin or cephalothin against methicillin-resistance Staphylococcus epidermidis. J Infect Dis. 1979 Apr;139(4):452–457. doi: 10.1093/infdis/139.4.452. [DOI] [PubMed] [Google Scholar]
  27. Spitzer P. G., Eliopoulos G. M. Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis. Ann Intern Med. 1984 Apr;100(4):533–534. doi: 10.7326/0003-4819-100-4-533. [DOI] [PubMed] [Google Scholar]
  28. Tofte R. W., Solliday J. A., Crossley K. B. Susceptibilities of enterococci to twelve antibiotics. Antimicrob Agents Chemother. 1984 Apr;25(4):532–533. doi: 10.1128/aac.25.4.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Watanakunakorn C. Antimicrobial susceptibility of 200 blood isolates of coagulase-negative staphylococci to 20 antimicrobial agents. Scand J Infect Dis. 1984;16(4):345–348. doi: 10.3109/00365548409073959. [DOI] [PubMed] [Google Scholar]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute

RESOURCES